checkAd

     120  0 Kommentare Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate - Seite 3

    Investor Contacts:    
    Will Brown   Ashley R. Robinson
    Chief Financial Officer   LifeSci Advisors, LLC
    Phone: 240-654-1450   617-430-7577
    wbrown@altimmune.com   arr@lifesciadvisors.com
         
    Media Contacts:    
    Warren Rizzi    
    Sard Verbinnen & Co.    
    Phone: 212-687-8080    
    altimmune-svc@sardverb.com     







    Lesen Sie auch

    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Verfasst von globenewswire
    Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate - Seite 3 GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal …